Evidence map›Paper›PMID 21899728›Full record

ArticleMolecular cancer2011

c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1.

Mario Campone, Bélinda Noël, Cécile Couriaud, Morgan Grau, Yannis Guillemin, Fabien Gautier, Wilfried Gouraud, Catherine Charbonnel, Loïc Campion, Pascal Jézéquel and 5 more

Open access · goldAbstract read
In one paragraph

Article in Molecular cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Dihydroceramide desaturase 1 (DES1) promotes anchorage-independent survival downstream of HER2-driven glucose uptake and metabolism.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2022
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2017
    Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Intracellular delivery system for antibody-Peptide drug conjugates.Molecular therapy : the journal of the American Society of Gene Therapy · 2015
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Mario CamponeCentre de Recherche en Cancérologie Nantes-Angers - UMR 892 - INSERM/Université de Nantes, Institut de Recherche Thérapeutique de l'Université de Nantes 8 Quai Moncousu BP 7072144007 Nantes Cedex 1 France.
Bélinda Noël
Cécile Couriaud
Morgan Grau
Yannis Guillemin
Fabien Gautier
Wilfried Gouraud
Catherine Charbonnel
Loïc Campion
Pascal Jézéquel
Frédérique Braun
Benjamin Barré
Olivier Coqueret
Sophie Barillé-Nion
Philippe Juin
Institut de Cancérologie de l'Ouest · FRCentre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers · FRInserm · FRNantes Université · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAnti-apoptotic signals induced downstream of HER2 are known to contribute to the resistance to current treatments of breast cancer cells that overexpress this member of the EGFR family. Whether or not some of these signals are also involved in tumor maintenance by counteracting constitutive death signals is much less understood. To address this, we investigated what role anti- and pro-apoptotic Bcl-2 family members, key regulators of cancer cell survival, might play in the viability of HER2 overexpressing breast cancer cells.

methodsWe used cell lines as an in vitro model of HER2-overexpressing cells in order to evaluate how anti-apoptotic Bcl-2, Bcl-xL and Mcl-1, and pro-apoptotic Puma and Bim impact on their survival, and to investigate how the constitutive expression of these proteins is regulated. Expression of the proteins of interest was confirmed using lysates from HER2-overexpressing tumors and through analysis of publicly available RNA expression data.

resultsWe show that the depletion of Mcl-1 is sufficient to induce apoptosis in HER2-overexpressing breast cancer cells. This Mcl-1 dependence is due to Bim expression and it directly results from oncogenic signaling, as depletion of the oncoprotein c-Myc, which occupies regions of the Bim promoter as evaluated in ChIP assays, decreases Bim levels and mitigates Mcl-1 dependence. Consistently, a reduction of c-Myc expression by inhibition of mTORC1 activity abrogates occupancy of the Bim promoter by c-Myc, decreases Bim expression and promotes tolerance to Mcl-1 depletion. Western blot analysis confirms that naïve HER2-overexpressing tumors constitutively express detectable levels of Mcl-1 and Bim, while expression data hint on enrichment for Mcl-1 transcripts in these tumors.

conclusionsThis work establishes that, in HER2-overexpressing tumors, it is necessary, and maybe sufficient, to therapeutically impact on the Mcl-1/Bim balance for efficient induction of cancer cell death.

Indexed as

ApoptosisApoptosis Regulatory ProteinsBcl-2-Like Protein 11bcl-X ProteinBreast NeoplasmsCell AggregationCell Line, TumorCell SurvivalErb-b2 Receptor Tyrosine KinasesEverolimusFemaleGene ExpressionGene Knockdown TechniquesHumansMechanistic Target of Rapamycin Complex 1Membrane ProteinsApoptosis Regulatory ProteinsBCL2L11 protein, humanBCL2L1 protein, humanBcl-2-Like Protein 11bcl-X ProteinERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesEverolimusMechanistic Target of Rapamycin Complex 1Membrane ProteinsMultiprotein ComplexesMYC protein, humanMyeloid Cell Leukemia Sequence 1 ProteinPMAIP1 protein, humanProteinsProto-Oncogene ProteinsProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-mycSirolimusTOR Serine-Threonine Kinases

Identifiers

PMID21899728
PMCPMC3175201
OpenAlexW2146674923

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.